|Bid||7.15 x 1200|
|Ask||22.00 x 800|
|Day's Range||9.38 - 9.90|
|52 Week Range||4.78 - 15.19|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||21.00|
Arcturus Appoints Senior VP of Business Development & Alliance Management and VP of Translational Biology. SAN DIEGO, Sept. 21, 2018-- Arcturus Therapeutics Ltd., a leading RNA medicines company, today ...
SAN DIEGO, Aug. 29, 2018-- Arcturus Therapeutics Ltd., a leading RNA medicines company, today announced that at the Company’ s Annual General Meeting of Shareholders on August 24, 2018, shareholders of ...
Arcturus Therapeutics Ltd. (ARCT), a leading RNA medicines company, today announced that it has appointed Andrew Sassine as Interim Chief Financial Officer (CFO), effective August 24, 2018. Mr. Sassine has served on Arcturus’ Board of Directors since May 2018 and will continue to serve on Arcturus’ Board of Directors. “In a short period of time since joining our Board in May, Andy has made significant contributions toward the financial stewardship of Arcturus – I am very pleased to have him join our leadership team in this interim, but important role,” said Joseph Payne, President & CEO of Arcturus Therapeutics.
SAN DIEGO, Aug. 27, 2018-- Arcturus Therapeutics Ltd., a leading RNA medicines company, today announced that Joseph E. Payne will present at the upcoming conferences, including the B. Riley FBR Annual ...
Arcturus Therapeutics Ltd. (ARCT), a leading RNA medicines company, today announced the achievement of key milestones as part of its agreement with Cystic Fibrosis Foundation (CF Foundation) Therapeutics, Inc. The completion of these success-driven milestones has triggered an undisclosed payment to Arcturus from the CF Foundation to advance LUNAR-CF, an mRNA therapeutic program to treat cystic fibrosis. Arcturus recently presented preclinical data at the Cystic Fibrosis Foundation Research Conference during June 18-21 in Jackson Hole, Wyoming. Given the success of the ongoing program, Arcturus and the CF Foundation have agreed to expand the scope of activities included in the research agreement and have amended the milestone criteria to further define the plan to advance the program into clinical development.
To approve the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018 and to authorize the board of directors of the Company (the “Board”) to determine its compensation. To approve an amended and restated Compensation Policy for the Company’s Office Holders. To approve the re-election as directors of the Board, until the next annual general meeting of the Company, of each of the following currently serving directors: Mr. Joseph Payne, Dr. Peter Farrell, Mr. Andy Sassine, Dr. Magda Marquet and Mr. James Barlow.
All Four Proposals Approved by Shareholders. SAN DIEGO, July 09, 2018-- Arcturus Therapeutics Ltd., a leading RNA medicines company, today announced that at its Extraordinary General Meeting of Shareholders ...
Stock Monitor: PLx Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 24, 2018 / Active-Investors.com has just released a free research report on Arcturus Therapeutics Ltd (NASDAQ: ARCT ) ("Arcturus"). ...